Aurora Cannabis Sees Q4 Growth In Medical Cannabis While Consumer Segment Declines Materially

Aurora Cannabis (TSX: ACB) saw revenue of $67.4 million in its fiscal fourth quarter on a net basis. The topline figure grew by 5% on a year over year basis, which the company largely attributes to strong growth in its global medical cannabis business, which saw growth of 20%.

The firms fiscal year 2023 notably consisted of only three quarters as a result of modifying the fiscal year. The results are for the period ended March 31, 2024.

Revenue during the quarter was largely attributable to the medical segment, which posted 20% growth year over year, ending the quarter at $45.6 million. Consumer cannabis meanwhile declined by 29%, falling to $10.2 million. Plant propagation fell by a less dramatic 3%, to produce revenues of $10.4 million during the quarter.

A total of 15,179 kilograms of cannabis were sold during the period, an 8% decline year over year, while the average net price of cannabis, excluding bulk sales, improved 13% to $5.37 per gram.

READ: Aurora Cannabis Replaces CFO, Conducts Reverse Split

Selling, general and administrative expenses for the quarter amounted to $31.6 million on an adjusted basis, which excludes $8.0 million in restructuring and non-recurring costs. Net loss for the period overall amounted to $20.8 million, whiled Adjusted EBITDA came in at $1.9 million.

In terms of the firms balance sheet, a final $7.2 million payment was made on a convertible senior note, resulting in the company now being debt free. Aurora’s cash position meanwhile sits at $180 million.

In terms of outlook, the company is calling for mid-to-high teens growth in net revenue on a percentage basis in the first quarter of fiscal 2025, while positive adjusted EBITDA should also be higher, along with operating cash flow.

Aurora Cannabis last traded at $7.73 on the TSX.


Information for this briefing was found via Sedar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

The Goal is Gold Production as Soon as Possible! | Gordon Robb – ESGOLD Corp.

Snowline Gold: The Multi Billion Dollar Valley PEA

Euro Sun: Rovina Copper-Gold Project Secures Some Major Funding

Recommended

Antimony Resources Drills 4.17% Antimony Over 7.4 Metres At Bald Hill

ESGold To Expand Mine Building At Montauban In Advance Of Gold & Silver Production

Related News

Aurora Cannabis Enters $27 Million Supply Agreement With SNDL

Aurora Cannabis (TSX: ACB) has entered into a major agreement with SNDL Inc (NASDAQ: SNDL)....

Friday, February 7, 2025, 08:45:26 AM

Aurora Cannabis Acquires Majority Stake In Former Zenabis Subsidiary Bevo Farms

The Canadian cannabis sector is flailing so bad when it comes to rejuvenating their operations...

Thursday, August 25, 2022, 08:29:20 AM

Aurora Cannabis Revenues Decline 26% To $56.0 Million, Losses Increase

Aurora Cannabis (TSX: ACB) (NYSE: ACB) released its second quarter financials this morning, reporting net...

Thursday, February 13, 2020, 08:00:33 AM

Aurora Cannabis Confirms Reverse Split Effective Monday

Aurora Cannabis (TSX: ACB) (NYSE: ACB) confirmed last night after the bell that it will...

Saturday, May 9, 2020, 08:30:00 AM

Aurora Cannabis: Stifel Lowers Rating To Hold, Price Target Falls To $10.50 From $16

Yesterday, Aurora Cannabis (TSX: ACB) (NYSE: ACB) provided a business update. The firm announced that...

Wednesday, September 9, 2020, 01:47:00 PM